METTL3 and breast carcinoma: Epitranscriptomic regulation play a vital role in gynecology-related cancer risk, especially in breast cancer, where the imbalance of RNA “writers” (e.g., METTL3), “readers” (e.g., YTHDF1/3), and “erasers” (e.g., FTO, ALKBH5) contribute to tumor development, cancer stem cell maintenance, metastasis, and resistance to treatment [105].